AbbVie Inc. $ABBV Shares Acquired by Franklin Street Advisors Inc. NC

Franklin Street Advisors Inc. NC grew its holdings in AbbVie Inc. (NYSE:ABBV) by 2.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 182,921 shares of the company’s stock after purchasing an additional 4,257 shares during the period. AbbVie makes up 2.4% of Franklin Street Advisors Inc. NC’s investment portfolio, making the stock its 12th largest position. Franklin Street Advisors Inc. NC’s holdings in AbbVie were worth $41,796,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of AbbVie by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock valued at $41,155,601,000 after purchasing an additional 448,554 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of AbbVie by 4.3% in the 3rd quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock valued at $2,779,426,000 after purchasing an additional 493,420 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares during the last quarter. Amundi lifted its stake in shares of AbbVie by 15.6% in the 3rd quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after purchasing an additional 1,414,621 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in shares of AbbVie by 4.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company’s stock valued at $2,241,363,000 after purchasing an additional 408,426 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie filed a lawsuit seeking clearer, narrower guidance on which patients qualify for a federal drug discount program — a step that could limit discount exposure and protect revenue/margins if the court or settlement tightens eligibility. AbbVie files lawsuit to address ‘outdated’ drug discount eligibility program
• Positive Sentiment: New dermatology data showcased at the AAD meeting (Skyrizi and Rinvoq long‑term outcomes, safety and expanded labels) support AbbVie’s immunology growth thesis and help de‑risk revenue concentration away from Humira. Can AbbVie’s (ABBV) New Dermatology Data Quietly Reshape Its Immunology-Heavy Investment Story?
• Positive Sentiment: Analyst support and dividend/cash‑flow strength: recent analyst notes (including high price targets from JPMorgan and an overweight stance from Cantor Fitzgerald despite a modest PT trim) plus strong free cash flow and a reliable dividend underpin investor confidence. AbbVie Gets JPMorgan Buying Opportunity Call With $260 Price Target Amid Competitive Concerns Cantor Fitzgerald lowers price target to $240, remains Overweight
• Neutral Sentiment: Broader health-care sector strength lifted stocks broadly today, providing a tailwind to ABBV alongside company‑specific news. Sector Update: Health Care Stocks Advance in Afternoon Trading
• Neutral Sentiment: Market commentary and trending coverage (Zacks, Seeking Alpha) are spotlighting AbbVie’s pipeline and dividend, keeping the name on investor radars but not adding new hard catalysts. AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: AbbVie added Humira to the TrumpRx program at a steep (reported ~86%) discount for broader access — a move that could pressure Humira residual revenues and overall pricing power in the U.S. over time. Humira’s TrumpRx Discount Raises New Questions For AbbVie Valuation
• Negative Sentiment: Valuation and guidance risks remain: some analysts and commentators flag that recent volatility, competitive pressures and any guidance softness could limit upside despite strong drug growth — a caution that can weigh on the stock if sentiment flips. Why The AbbVie (ABBV) Story Is Shifting As Immunology Hopes Meet Valuation Doubts

AbbVie Trading Up 2.6%

ABBV stock opened at $211.74 on Thursday. The company has a market capitalization of $374.40 billion, a PE ratio of 89.72, a P/E/G ratio of 0.73 and a beta of 0.38. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The business’s fifty day moving average price is $220.80 and its 200 day moving average price is $224.19.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.3%. AbbVie’s dividend payout ratio is 293.22%.

Insider Activity

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.25% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

ABBV has been the topic of several recent analyst reports. Evercore decreased their price target on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. Morgan Stanley boosted their price objective on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. UBS Group cut their price objective on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. BMO Capital Markets reiterated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Finally, Piper Sandler boosted their price objective on AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $252.65.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.